Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06412510 | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT | active not recruiting | Phase 1 / Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06915025 | Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer(OVATION-3) | recruiting | Phase 3 | 500 | ImunonINDUSTRY | 1 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07259616 | Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities | completed | — | 46,079 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 0 | Sep 15, 2026 | clinicaltrials |
| NCT07303894 | A Study of Isoquercetin in People With Ovarian Cancer | recruiting | Phase 2 | 90 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07429487 | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for Cancer(WATCH AND ACT) | recruiting | N/A | 98 | Centre Antoine LacassagneOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT00791635 | Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer | active not recruiting | — | 79 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01012817 | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | active not recruiting | Phase 1 / Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04575935 | Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | recruiting | Phase 3 | 580 | M.D. Anderson Cancer CenterOTHER | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04723095 | Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix(NeCTuR) | recruiting | — | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05059444 | ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation(ORACLE) | recruiting | — | 2,285 | Guardant Health, Inc.INDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07772869 | Uterine Lavage to Detect Ovarian Cancer Risk | recruiting | N/A | 75 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04633239 | Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04905082 | HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics | active not recruiting | N/A | 465 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe) | active not recruiting | Phase 1 / Phase 2 | 320 | Ascendis Pharma Oncology Division A/SINDUSTRY | 10 | Sep 11, 2026 | clinicaltrials |
| NCT06964009 | DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer | recruiting | Phase 1 | 30 | Elizabeth Stover, MD, PhDOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07764744 | Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants(OC-LEAD) | not yet recruiting | N/A | 70 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02101775 | Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 124 | National Cancer Institute (NCI)NIH | 3 | Sep 10, 2026 | clinicaltrials |
| NCT02397083 | Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer(LEVER) | active not recruiting | Phase 2 | 102 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07811271 | Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | not yet recruiting | Phase 3 | 600 | BeOne MedicinesINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07812636 | Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer(TIDE) | not yet recruiting | Early Phase 1 | 15 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 349 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02595892 | Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03367741 | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer | active not recruiting | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China(RAINFOL-02) | recruiting | Phase 3 | 82 | GenmabINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT04585958 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | recruiting | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT02208375 | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | active not recruiting | Phase 1 | 159 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04315233 | Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics(CHARGE) | terminated | Phase 1 | 12 | University of UtahOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05139368 | Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer(RT-PACE) | active not recruiting | N/A | 22 | University of UtahOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT01617382 | Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed(HIPEC) | recruiting | — | 125 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05521997 | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05950464 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | recruiting | Phase 1 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 156 | Context Therapeutics Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07755436 | Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. | recruiting | Phase 1 | 180 | ArriVent BioPharma, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07796672 | Feasibility Study of Blood Biomarker Identification in Cervical Cancer(CLARITY) | recruiting | — | 100 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Sep 2, 2026 | clinicaltrials |
| NCT00086567 | Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers | completed | — | 119 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT02880007 | Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer(TRIDICOL) | completed | Phase 2 | 48 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07791732 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) | not yet recruiting | Phase 3 | 600 | Daiichi SankyoINDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT04839614 | Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 31, 2026 | clinicaltrials |
Data updated 15 days agoSource updated Sep 15, 2026source: clinicaltrials